72% Increase in this Cholera Vaccine Revenues

Following the end of the recent pandemic, many travelers explored new destinations in 2023. However, over 667,000 cholera cases and 4,000 deaths were reported last year.

In countries experiencing cholera outbreaks, international travelers protected themselves with safe and effective vaccines.

Since the beginning of 2023, there have been 24 reactive cholera vaccination campaigns implemented in 12 countries.

But, there is a global shortage of cholera vaccines. From January 2023 to January 2024, 76 million oral cholera vaccines (OCV) were requested by 14 countries, while only 38 million doses were available.

The World Health Organization (WHO) has three pre-qualified OCVs: Dukoral®, Shanchol™, and Euvichol®.

One of these OCV manufacturers reported a 72% increase in revenues today.

On February 15, 2024, Valneva SE reported its revenue for 2023. Last year, sales of Valneav's DUKORAL® vaccine amounted to €29.8 million (US32 million), a significant increase from the €17.3 million recorded in 2022.

This significant increase can be attributed to the recovery of the private travel markets and price hikes. However, the company says that foreign currency fluctuations caused a reduction of €0.9 million in DUKORAL® sales.

In a press release, Peter Bühler, Valneva's Chief Financial Officer, commented, "In 2023, Valneva successfully executed key strategic objectives despite a difficult economic environment.... we are entering 2024 in a good financial position to support our commercial and R&D objectives."

In the United States, access to cholera vaccines is limited.